Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Investment analysts at HC Wainwright began coverage on shares of Rezolve AI (NASDAQ:RZLV – Get Free Report) in a research ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Ryvyl (RVYL – Research Report) today. The company’s shares closed yesterday at ...

H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could ...

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

A webcast replay will be available on the VYNE website for 90 days following the event. About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps a Buy rating on the shares.

Detailed price information for Gryphon Digital Mining Inc (GRYP-Q) from The Globe and Mail including charting and trades.

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...